Fan Genhao, Liu Menglin, Liu Jia, Chen Xixi, Huang Yuhong
Tianjin University of Chinese Medicine, Tianjin 301617, China.
Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Evid Based Complement Alternat Med. 2022 Feb 15;2022:6650763. doi: 10.1155/2022/6650763. eCollection 2022.
The aim of this study was to systematically review the efficacy and safety of Shuxuening injection combined with conventional Western medicine in the treatment of unstable angina. Randomized controlled trials of Shuxuening injection combined with conventional Western medicine in the treatment of unstable angina were searched by the computer system from PubMed, EMBASE, Cochrane Library, VIP, CNKI, Wanfang Database, and Chinese Biomedical Database since the establishment of the database until June 2020, according to the inclusion and exclusion criteria for the selection of literature, using Rev Man5.3 Meta-analysis Software. The 28 randomized controlled trials were included, with a total of 3,127 patients. Meta-analysis results showed that Shuxuening injection combined with conventional western medicine was effective in improving the clinical efficacy of angina pectoris (RR = 1.23, 95% CI [1.19, 1.27], <0.00001), improvement of ECG (RR = 1.31, 95% CI [1.23, 1.40], < 0.00001), reduction of angina pectoris attack frequency (MD = -1.28, 95% CI [-1.88, -0.67], < 0.0001), duration of angina (MD = -3.36, 95% CI [-3.69, -3.03], < 0.00001), nitroglycerin dosage (MD = -0.39, 95% CI [-0.65, -0.13], = 0.003), C-reactive protein (MD = -2.72, 95% CI [-3.41, -2.03], < 0.00001), BNP (MD = -23.33, 95% CI [-27.87, -18.79], < 0.00001), lower triglycerides (MD = -0.72, 95% CI [-1.05, -0.38], < 0.0001), total cholesterol (MD = -1.39, 95% CI [-1.84, -0.94], < 0.00001), and LDL cholesterol (MD = -1.20, 95% CI [-2.12, -0.29], = 0.01) which is better than that of control group. The effect on raising HDL cholesterol was comparable between the two groups (MD = 0.49, 95% CI [-0.06, 1.04], = 0.08) and the incidence of adverse reactions to differences had no statistical significance (RR = 0.99, 95% CI [0.54, 1.81], = 0.97). The Shuxuening injection combined with conventional Western medicine in the treatment of unstable angina has clear efficacy and a certain degree of safety, so it is recommended for clinical application.
本研究旨在系统评价舒血宁注射液联合传统西药治疗不稳定型心绞痛的疗效及安全性。自数据库建立至2020年6月,通过计算机系统检索PubMed、EMBASE、Cochrane图书馆、维普、中国知网、万方数据库和中国生物医学数据库中舒血宁注射液联合传统西药治疗不稳定型心绞痛的随机对照试验,根据文献纳入和排除标准筛选文献,采用Rev Man5.3软件进行Meta分析。共纳入28项随机对照试验,共计3127例患者。Meta分析结果显示,舒血宁注射液联合传统西药能有效提高心绞痛临床疗效(RR = 1.23,95%CI[1.19,1.27],<0.00001)、改善心电图(RR = 1.31,95%CI[1.23,1.40],<0.00001)、降低心绞痛发作频率(MD = -1.28,95%CI[-1.88,-0.67],<0.0001)、缩短心绞痛持续时间(MD = -3.36,95%CI[-3.69,-3.03],<0.00001)、减少硝酸甘油用量(MD = -0.39,95%CI[-0.65,-0.13],P = 0.003)、降低C反应蛋白(MD = -2.72,95%CI[-3.41,-2.03],<0.00001)、脑钠肽(MD = -23.33,95%CI[-27.87,-18.79],<0.00001)、降低甘油三酯(MD = -0.72,95%CI[-1.05,-0.38],<0.0001)、总胆固醇(MD = -1.39,95%CI[-1.84,-0.94],<0.00001)及低密度脂蛋白胆固醇(MD = -1.20,95%CI[-2.12,-0.29],P = 0.01),优于对照组。两组在提高高密度脂蛋白胆固醇方面效果相当(MD = 0.49,95%CI[-0.06,1.04],P = 0.08),不良反应发生率差异无统计学意义(RR = 0.99,95%CI[0.54,1.81],P = 0.97)。舒血宁注射液联合传统西药治疗不稳定型心绞痛疗效确切且具有一定安全性,建议临床应用。